Related Experiment Video
Updated: Jan 4, 2026
Intraoperative Assessment of Resection Margins in Oral Cavity Cancer: This is the Way
Published on: May 10, 2021
Impact of Acridine Orange in Patients With Soft Tissue Sarcoma Treated With Marginal Resection
Hiroyuki Tsuchie1, Makoto Emori2, Naohisa Miyakoshi3
1Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan tuchikiti@yahoo.co.jp.
Background/Aim:
Although few studies have shown the effectiveness of adjuvant therapy with acridine orange (AO) for soft tissue sarcoma (STS) patients, no study has investigated this among cases with marginal resection. The aim of the study was to evaluate the effectiveness of AO therapy directly by comparing it to marginal resection cases that did not receive AO.
Patients And Methods:
This retrospective study included 19 and 33 patients with STS who received AO therapy (AO group) and marginal resection without AO therapy (non-AO group), respectively. The patients' clinical information was collected, and the clinical courses were compared.
Results:
The local recurrence rate in the AO group was significantly lower than that in the non-AO group (p<0.05). The local recurrence-free survival curves significantly differed between the two groups (p<0.05). High grade malignancy and no treatment with AO were identified as risk factors for local recurrence (p<0.05).
Conclusion:
AO therapy strongly suppressed local recurrence after marginal resection of STS.
Insights
Acridine orange (AO) adjuvant therapy significantly reduced local recurrence in soft tissue sarcoma (STS) patients undergoing marginal resection. This finding highlights AO therapy as a crucial treatment for improving outcomes in STS.
Area of Science:
- Oncology
- Surgical Oncology
- Pharmacology
Background:
- Soft tissue sarcoma (STS) is a rare malignancy.
- Adjuvant therapies are crucial for managing STS, especially after incomplete resection.
- The role of acridine orange (AO) as an adjuvant therapy in STS, particularly after marginal resection, remains under-investigated.
Purpose of the Study:
- To evaluate the effectiveness of acridine orange (AO) adjuvant therapy in soft tissue sarcoma (STS) patients who underwent marginal resection.
- To compare local recurrence rates between STS patients treated with AO therapy and those who received marginal resection without AO.
Main Methods:
- Retrospective study comparing two groups of STS patients: those receiving AO therapy (AO group, n=19) and those undergoing marginal resection without AO (non-AO group, n=33).
- Collection and comparison of clinical information and patient outcomes.
- Statistical analysis to determine the significance of differences in local recurrence rates and survival curves.
Main Results:
- The AO group exhibited a significantly lower local recurrence rate compared to the non-AO group (p<0.05).
- Local recurrence-free survival curves were significantly different between the two treatment groups (p<0.05).
- High-grade malignancy and absence of AO treatment were identified as independent risk factors for local recurrence (p<0.05).
Conclusions:
- Acridine orange (AO) adjuvant therapy demonstrates significant efficacy in suppressing local recurrence following marginal resection of soft tissue sarcoma (STS).
- AO therapy should be considered as a valuable adjuvant treatment to improve local control in STS patients with marginal resection.
